Last reviewed · How we verify
Paxlovid (Copackaged) (pf-07321332)
Paxlovid works by inhibiting the activity of an enzyme that the SARS-CoV-2 virus needs to replicate.
Paxlovid, developed by Pfizer, holds a dominant market position as one of the leading antiviral treatments for COVID-19, with potential to be the world's best-selling drug. Its competitive advantage lies in its mechanism of action, which effectively inhibits the viral replication enzyme essential for SARS-CoV-2. A key risk is the presence of strong competition from other protease inhibitors such as saquinavir, indinavir, ritonavir, nelfinavir, and amprenavir. Despite having no ongoing clinical trials, Paxlovid's future pipeline outlook remains robust, supported by its approved indication and the potential for expanded use through PD-L1 companion diagnostics.
At a glance
| Generic name | pf-07321332 |
|---|---|
| Sponsor | Pfizer |
| Therapeutic area | Infectious Disease |
| Phase | discontinued |
| First approval | 2023 |
Mechanism of action
Think of it like a key that fits into a lock. The SARS-CoV-2 virus has a special enzyme that it needs to make copies of itself, and Paxlovid is like a key that blocks that enzyme from working. This helps to slow down the spread of the virus in the body.
Approved indications
- COVID-19
Common side effects
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paxlovid (Copackaged) CI brief — competitive landscape report
- Paxlovid (Copackaged) updates RSS · CI watch RSS
- Pfizer portfolio CI